Leprosy Mailing List – September 8, 2026
Ref.: (LML) Long-lasting adverse impact of chemoprophylaxis & what actually works
From: Sandra Maria Barbosa Durães, Rio de Janeiro, Brazil
____________________________________________________________________________
Dear Pieter and colleagues,
It is interesting to note that people use arguments favouring scientific evidence when they assume it supports their own opinions, yet reject that same evidence when it does not suit their purposes. Thus, I believe it is equally important to ask: What level of evidence is required for unestablished and unapproved therapeutic regimens—such as extending treatment beyond 12 doses or using daily rifampicin—to be considered safe enough for large-scale implementation, as some advocate ?
Best regards,
Sandra Maria Barbosa Durães
Associated Professor Clinical Medicine Department - MMC
Fluminense Federal University - UFF
+5521997370722
____________________________________________________________________________
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << edit...@gmail.com
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/939c49da-75cf-49f3-98fb-9ebbf220b6f6n%40googlegroups.com.
No comments:
Post a Comment